# iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes

> **NCT03446638** · NA · WITHDRAWN · sponsor: **University of Florida**

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** FDA-approved drug or combination of drugs
- **DRUG:** FLAG induction
- **DRUG:** 7 + 3 induction
- **DRUG:** Low-dose cytarabine
- **OTHER:** Supportive care alone
- **DEVICE:** Computational biology simulations software

## Key facts

- **NCT ID:** NCT03446638
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-05
- **Primary completion:** 2021-08
- **Final completion:** 2022-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** administratively withdrawn
- **Last updated:** 2019-06-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03446638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03446638, "iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03446638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*